七部门发布脑机接口重磅政策！产业发展提速，监管挑战仍在

Core Viewpoint - The brain-computer interface (BCI) industry is accelerating towards a sustainable development model, with the release of the implementation opinions by seven government departments aimed at fostering innovation and application in the sector [3][4]. Group 1: Policy and Strategic Goals - The implementation opinions outline five key tasks and 17 specific measures to enhance the BCI industry, aiming for breakthroughs in key technologies by 2027 and establishing a competitive industrial ecosystem by 2030 [3][4]. - By 2027, the goal is to achieve international advanced levels in electrode, chip, and complete product performance, with applications in industrial manufacturing, healthcare, and consumer life [3][4]. Group 2: Industry Development and Application - The BCI industry is transitioning from a fragmented policy approach to a coordinated national strategy, focusing on rapid development and strategic layout [6]. - Key tasks include strengthening hardware and software development, promoting the application of technological achievements, and enhancing testing and pilot capabilities [6][7]. Group 3: Funding and Investment - The implementation opinions emphasize increased policy support and funding for the BCI sector, including the integration of technology and finance to attract more capital [7][8]. - Financial support is expected to accelerate the development of core components and systems in the BCI industry, particularly in critical areas like biocompatible materials and minimally invasive implantation techniques [8]. Group 4: Standardization and Regulatory Challenges - The sustainable development of the BCI industry relies on establishing a standard system for communication protocols and data governance to ensure safety and interoperability [10][11]. - The opinions highlight the need for a data governance framework to protect user information and enhance the security of biological digital information [10][11]. Group 5: Clinical and Research Considerations - There are significant challenges in ensuring the safety and clinical value of invasive BCI products, necessitating comprehensive clinical research and evidence chains [12][13]. - The industry faces issues such as fragmented resources, unstandardized interfaces, and a lack of alignment between clinical needs and payment capabilities, which require regulatory innovations and collaborative efforts [13].